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S100P enhances the motility and 
invasion of human trophoblast cell 
lines
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S100P has been shown to be a marker for carcinogenesis where its expression in solid tumours 
correlates with metastasis and a poor patient prognosis. This protein’s role in any physiological process 
is, however, unknown. Here we first show that S100P is expressed both in trophoblasts in vivo as well 
as in some corresponding cell lines in culture. We demonstrate that S100P is predominantly expressed 
during the early stage of placental formation with its highest expression levels occurring during the 
first trimester of gestation, particularly in the invading columns and anchoring villi. Using gain or loss 
of function studies through overexpression or knockdown of S100P expression respectively, our work 
shows that S100P stimulates both cell motility and cellular invasion in different trophoblastic and first 
trimester EVT cell lines. Interestingly, cell invasion was seen to be more dramatically affected than 
cell migration. Our results suggest that S100P may be acting as an important regulator of trophoblast 
invasion during placentation. This finding sheds new light on a hitherto uncharacterized molecular 
mechanism which may, in turn, lead to the identification of novel targets that may explain why 
significant numbers of confirmed human pregnancies suffer complications through poor placental 
implantation.
Trophoblast invasion of the decidualised endometrium to establish the precursor of the placenta, the first step of 
implantation, is a tightly regulated process, orchestrated by the continuous cross-talk between foetal and mater-
nal compartments. During this stage, one of the prominent factors for proper embryonic development is the 
successful migration and invasion of extravillous trophoblast cells into the maternal decidua and myometrium. 
Shallow implantation, in contrast, is thought to lead to poor blood and nutrient supplies to the developing foetus, 
ultimately resulting in pregnancy conditions such as foetal growth restriction, preeclampsia and miscarriages.
A class of proteins that has been linked to the process of placentation development and pregnancy disorders is 
the S100 family of calcium-binding proteins. This family of approximately 25 different proteins is characterised by 
the presence of a pair of calcium-binding helix-loop helix domains (EF hand regions) at either end of the protein 
sequences. Whilst these proteins do not contain intrinsic enzymatic activities of their own, their interaction with 
specific partners regulates a large number of cellular components and biological processes both intracellularly and 
extracellularly. For instance, upregulation of both S100A6 and S100A12 has been linked to increases in preec-
lampsia1,2. Expression of other S100 proteins in the process of placentation has been reported with the majority 
concentrated on this expression on the maternal/endometrial sides, where, for instance S100G (also known as 
Calbindin-d9k)3, CaBP-d28k4, S100A105 and S100A116 have been linked to regulating endometrial receptivity. 
Reports of occurrence of S100 protein expression from the foetal side have been more infrequent, although for 
example, CaBP-d28k has been reported to be expressed in trophoblast Jeg-3 cells7 and in vivo8, whilst S100B, 
S100A4, S100A6 and S100A8 expression have been observed in trophoblasts9–12. However the true functions of 
S100 proteins in either the endometrium or trophoblasts remain unknown.
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Another S100 factor, S100P has been shown to be expressed in the placenta13,14 and is thought to play impor-
tant roles during placentation, where it is found at a concentration 90–200-fold higher than in any other organs15. 
Its expression also occurs in the endometrial tissue, predominantly in the endometrial epithelial and stromal 
cells, where its increasing levels correlate with those of P4 progesterone upon stimulation16. Its expression is 
also dramatically upregulated during the formation of the receptive window, an observation that appeared to be 
S100P specific, since only minor changes were seen with other S100 proteins studied17. S100P has also recently 
been reported to be expressed in trophoblasts18–20, but the role of this protein in the implantation process remains 
obscure.
Our work in this report demonstrates that S100P can stimulate the motile and invasive properties of troph-
oblasts. We show that this protein is greatly expressed in human trophoblasts in vivo. Expression is seen in the 
extravillous populations of the anchoring columns, with an overall expression seen to be at its highest during 
the early stages of implantation in the first trimester of gestation. High levels of S100P expression can equally 
be observed in two human placental-derived trophoblastic cell lines Jeg-3 and Bewo. Interestingly high levels 
of S100P expression promote both motility and invasion in these lines since its specific down-regulation using 
targeted siRNA technology is sufficient to abrogate these properties. Cellular analysis also demonstrates that 
reduced levels of S100P leads to dramatic changes in cytoskeletal remodelling. The reciprocal experiment, using 
the first trimester HTR8/SVneo extravillous trophoblast cell line, in which S100P expression is overexpressed, 
equally demonstrates that high levels of S100P correlates with significant increases in motility and invasion. Our 
data therefore demonstrates a new function for S100P which links its well characterised motility and invasion- 
enhancing properties to a physiological process, that of placental implantation.
Material and Methods
Human Placental tissues. Written informed consent was obtained from all women recruited into the study. 
Samples of placenta tissues obtained immediately after elective termination of pregnancy from first trimester of 
gestation (8–11 weeks; n = 5), second trimester (15–20 weeks; n = 4), or third trimester (32–38 weeks; n = 7) were 
collected using mifepristone and misoprostol or from pregnancies delivered by elective Caesarean with tissues 
processed as described previously21. Placental samples were collected with approval of Health Research Authority 
- West Midlands, Edgbaston Research Ethics Committee (NHS REC 06/Q2707/12 [2006 approval]) (RG_14–194 
[10.2014 approval]) and by the Lothian Research Ethics Committee (NHS REC 09/S0704/3). Samples were fixed 
with formaldehyde and embedded into paraffin wax prior to further processing. For all samples, written informed 
consent was obtained and all methods were performed in accordance with the NHS and HRA guidelines.
Cell Lines and culture. The two human placental derived choriocarcinoma trophoblastic cell lines Jeg-3 and 
Bewo were a kind gift of Dr. Emmanouil Karteris (Brunel University). The HTR8/SVneo first trimester extravil-
lous (EVT) trophoblasts were a gift of Prof. Graham Charles (Queen’s University, Kingston, Ontario (Canada)) 
These cell lines are some of the best characterised lines to study motility and invasion in respect to implantation/
placentation22. The human cancer cell line HeLa A3 expressing the S100P protein under the control of a dox-
ycycline inducible promoter has been reported previously23. Cells were cultured with 5% (v/v) CO2 and 20% 
(v/v) O2 at 37 °C in MEM (for Jeg-3), F-12 medium (for Bewo), RPMI (HTR8/SVneo) and normal DMEM (for 
HeLa), supplemented with 10% (v/v) Fetal Bovine Serum (FBS), 100 units and 0.1 mg/ml Penicillin/streptomycin 
respectively and 2mM L-glutamine. Trophoblast cells were passaged using 0.025% (w/v) trypsin in 2.5 mM EDTA 
and all experiments were conducted with cells within 10–15 passages. The HeLa A3 inducible cells were grown, 
induced and treated as previously described23. In the context of our experiments, using HeLa A3 cells as both 
positive and negative controls, induction was promoted for 48–72 hours with 1.5 μg/ml doxycycline addition.
Stably expressing S100P HTR8/SVneo cell lines. The HTR8/SVneo cells were grown on 6 well plate 
to 70–80% confluency at the time of transfection (500,000 cells/well) in RPMI 1640 medium supplemented with 
5% (v/v) FCS for 24 hours prior to transfection with SGB217 with Lipofectamine 3000 (Invitrogen) following 
manufacturers’ instructions and the clones selected using 50 μg/ml hygromycin B. Plasmid SGB217 was obtained 
by in vivo recombination of pcDNA3.1 Hygro plasmid (ThermoFisher, UK) with a PCR amplified S100P product 
using SLiCE (Seamless ligation cloning extract). The successfully growing clones were isolated and transferred to 
24 well plate to grow up separately in medium with hygromycin B before expansion and further characterisation.
siRNA S100P and control delivery. Cells seeded (30000 Jeg3 cells and 60000 Bewo cells) in 24 well 
plates were grown for 2 days (Jeg-3) or 5 days (Bewo) prior to being transfected with 5 nM double-stranded 
siRNA (Qiagen, UK) for S100P (siRNA 4: SI00709940 and siRNA 6: SI03247013;) or with a mock control siRNA 
(SI03650318) in OptiMEM (Gibco, UK) and normal medium using 2 μl/well INTERFERin transfection reagents 
(Polyplus, France) following the manufacturer’s instructions. Cells were left in the presence of the different siR-
NAs for 48 hours prior to collection for qPCR or 72 hours for Western blotting analysis (See below). For motility/
invasion and immunostaining, cells were left to grow for 48 hours prior to starting the experiment.
Cell counting and viability using trypan blue exclusion. Cells treated with different siRNA (as above) 
or HTR8 cells were seeded at a density of 20000 cells per well in 24 well plates and grow for a further 24–48 hours 
incubation. At each respective time point, cells were removed using 0.025% (w/v) trypsin in 2.5 mM EDTA, 
diluted in serum-containing medium before centrifuging and resuspension in a mixture of 100 μl PBS/trypan 
blue. Cell numbers were calculated by haemocytometer counting and established as number of cells/well. Data 
is presented as percentage means ± SD of 3 independent experiments relative to controls over the course of the 
study.
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Western blotting. Following siRNA treatment for 72 hours, cells were collected by scrapping in 1 × PBS 
with 1x cocktail protease inhibitors (Sigma, UK) prior to sonication and dilution in 5x Laemmli buffer24. Protein 
lysates (25 μg) were loaded onto 16% (w/v) polyacrylamide gels and transferred to PVDF membranes with 30 mA 
per blot for 2 hours prior to blocking in blocking buffer (3% (w/v) BSA in PBS). Polyclonal goat anti S100P (R&D, 
UK) or monoclonal mouse/rabbit antibodies to α-tubulin and β-actin (Abcam, UK) antibodies were diluted in 
blocking buffer (Supplementary Table S1) and incubated overnight at 4 °C, prior to washing and incubation with 
the relevant secondary antibodies conjugated to HRP and ECL development (anti-goat or anti-rabbit/mouse 
(Supplementary Table S1)). For quantification purposes, levels of S100P were measured by densitometry anal-
ysis after Western blotting and normalised to the housekeeping proteins β-actin or α-tubulin for all samples. 
Densitometry quantification are presented as means ± SD of 3 independent experiments.
qPCR analysis. Following the appropriate incubation, trophoblast cells were collected after trypsini-
sation and mRNA extraction was carried out using TRIS reagent (Sigma, UK) according to the manufactur-
er’s protocol. qPCR was performed using S100P (sequences F: 5′-TCAAGGTGCTGATGGAGAA-3′ and R: 
5′-ACACGATGAACTCACTGAA-3′) and β-actin primers (F: 5′-ATGTACGTTGCTATCCAGGC-3′ and R: 
5′-CTCCTTAATGTCACGCACGAT-3′) and SYBR green mix (Roche, UK) according to the manufacturer’s pro-
tocols. Data of an individual representative experiment is presented as the mean values ± SD of 3 independent 
samples relative to controls.
Immunofluorescent staining. Immunofluorescence was carried out as previously described25. Briefly 
trophoblast-derived cell lines Bewo and Jeg-3 cells either untreated or 48 hours following siRNA treatments were 
plated at a concentration of 25,000 cells/well onto fibronectin-coated (2.5 μg/cm²) glass coverslips in a 24-well 
plate. After a 24 hour incubation, cells were washed once in cytoskeleton buffer (CB: 150 mM NaCl, 5 mM 
MgCl2, 5 mM EGTA, 5 mM glucose, 10 mM 2-(N-morpholino) ethanesulfonic acid, pH 6.1) and fixed with 3.7% 
(w/v) paraformaldehyde in CB at 37 °C for 20 min followed by permeabilisation with 5% (v/v) Triton X-100 in 
CB for 2 min and blocking with blocking solution (5% (v/v) goat serum in CB) for 60 min. Primary antibody 
incubation (Supplementary Table S1) against S100P and paxillin in blocking solution (1% (v/v) goat serum in 
CB) was incubated for 45 min at 37 °C. After washing three times with 1% (v/v) goat serum in CB, cells were 
incubated with the appropriate secondary anti-rabbit or anti- mouse antibodies labelled with FITC or TRITC 
(Supplementary Table S1) respectively in blocking solution for 45 min at 37 °C. For actin staining, rhodamine 
phalloidin (Invitrogen, Paisley, UK) was also added with secondary antibodies at a concentration of 0.6 μM. After 
washing with blocking solution, coverslips were rinsed once with water and mounted in Vectashield mounting 
medium (Vector Labs, UK), before being viewed using an Epifluorescence Leica DMI400B microscope equipped 
with a 63x oil objective. Images of an individual representative experiment are presented. Quantification of focal 
adhesions was carried out by counting the number of focal adhesions per cell selected at random and are pre-
sented as means ± SD of 3 independent experiments.
For immunofluorescent staining of the wound assay, Jeg-3 either non-treated or 48 hours following siRNA 
treatments, were plated at a concentration of 50,000 cells/well onto fibronectin-coated (2.5 μg/cm²) glass cover-
slips in a 24-well plate and grown for 48 hours. The confluent monolayers were scored with a sterile pipette tip 
to leave a scratch of approximately 0.4–0.5 mm in width. Culture medium was removed and replaced with fresh 
medium. Cells were left to grow for a further 16 hours prior to staining.
Immunohistochemistry. Immunohistochemical staining for S100P and counterstaining were performed 
simultaneously on human placental tissues as previously described26. All procedures and counterstaining for the 
groups were undertaken on the same day using the same reagents. Whenever required, staining was also per-
formed on serial sections for multi-staining procedures. Tissue sections were deparaffinised, and heat-induced 
antigen-retrieval were performed in citrate buffer (pH 6.0) using a pressure cooker (Prestige Medical, UK). 
Non-specific protein binding was blocked by incubation with either 1% (v/v) normal bovine serum and 5% (v/v) 
goat IgG (Vector Labs, UK) or 10% (v/v) normal swine serum (Vector Labs, UK) for 1 hour and sections were 
then incubated with a goat polyclonal anti-S100P antibody (R&D, UK), a rabbit monoclonal anti-S100P antibody 
(Abcam, UK), a mouse monoclonal anti-HLA-G antibody (Abcam, UK), a rabbit polyclonal anti-CD49f (inte-
grin α6) antibody (Abcam, UK) or an mouse monoclonal anti cytokeratin7 antibody (Leica Biosystems, UK) at 
4 °C overnight (Supplementary Table S1). After washing in 0.1% (v/v) Tween 20 (Sigma-Aldrich, UK) in Tris 
buffered Saline pH 7.4, sections were then incubated with the appropriate second antibody conjugated to horse-
radish peroxidase (HRP, Supplementary Table S1). The staining was analyzed using a Nano Zoomer XR scanner 
(Hamamatsu) and image acquisition using NDP software. Image analysis was conducted using Image-J analysis 
software. Images of an individual representative experiment are presented.
Motility/invasion assay. Motility and invasion abilities were measured using 8 μms Boyden polycarbonate 
transwell membranes (Greiner, UK). Following siRNA treatment for 48 hours and serum deprivation by growing 
the cells in 0.5% (v/v) FBS-containing medium for a further 24 hours, 105 cells were seeded in 0.5% (v/v/) FBS 
containing medium on without (motility) or with congealed matrigel (1:3 with serum free media Sigma, UK) 
against a gradient of 10% (v/v) FBS medium in the outer wells. Cells were left to migrate through the membranes 
for 24 hours prior to fixing and staining using the Diffquik histochemical kit (Reagena, Finland) following the 
manufacturer’s instructions.
Stained cells on the upper surface of the membrane were removed and those on the lower side of the mem-
brane were counted using a light microscope with an x20 objective lens, selecting 5 random fields. Data is pre-
sented as the means ± SEM of 3 or 4 independent experiments relative to controls (percentage) from 4 replicate 
wells for each set of conditions (Total cell numbers counted are available in Supplementary Tables S2 and S3). 
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Figure 1. S100P is expressed in trophoblasts including extravillous trophoblasts and more significantly during 
the first trimester in placental tissues. Expression of S100P proteins was analysed on both lysates (A,B) and 
sections (C,E) obtained from different paraffin-embedded placental samples from different gestational periods 
(first trimester (n = 5), second trimester (n = 4), or third trimester (n = 7). Proteins extracted from paraffin-
embedded placental block sections (1st trimester; 2nd trimester and 3rd trimester) at equal loading were separated 
by SDS-PAGE electrophoresis. Western blotting was carried out and membranes probed for S100P or α-tubulin 
and cropped images are presented (A). Levels of S100P were measured by densitometry analysis after Western 
blotting and normalised to α-tubulin for all samples (first trimester (n = 5), second trimester (n = 4), or third 
trimester (n = 7). Data is presented as percentage means ± SD of 2 independent experiments compared to the 
first trimester (B). Immunohistochemistry staining using a goat polyclonal S100P antibody and counterstaining 
on human placental tissues was performed as described in Methods. Arrows indicate cytotrophoblast cells 
(CT), syncytium (ST). Stroma is also highlighted. Bar corresponds to 150 μm (C). Quantification of S100P 
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Images of representative fields of motility/invasion assays were taken with the EVOS XL Cell Imaging System at 
x20 magnification.
Chemotaxis assay. Migration and chemotaxis abilities were measured using the Dunn chamber motility 
assay in DC100 Hawksley chambers. Following siRNA treatment for 48 hours and serum-deprivation in 0.5% 
(v/v) FBS-containing medium for a further 24 hours, 105 cells were seeded in 0.5% (v/v) FBS-containing medium 
for a minimum of 5 hours on pre-coated fibronectin coverslips. Coverslips and chambers were setup accord-
ing to previously published protocols27 prior to incubation in Cellstar 4 well plates (Greiner, UK). Digitised 
images were recorded using the Cell IQ automated image capture system, (Chip-Man Technologies, Finland) 
in which pre-selected fields were imaged using phase-contrast microscopy on a continuous loop for 24 hours. 
Quantification of migration and chemotaxis of an individual representative experiment was analysed by tracking 
of single cells (n = 20) using Image J with chemotaxis and migration tool plugins.
Deparaffinisation of embedded placental tissues for protein lysate preparation. Samples were 
processed using the protocol for protein extraction from formalin-fixed paraffin embedded specimens28. Briefly, 
5 tissues sections (10 μm each) were deparaffinised with a mixture of octane and methanol prior to drying and 
resuspension in 20 mM Tris-HCl buffer (pH 7) containing 2% (w/v) SDS prior to protein extraction using a 1 mL 
syringe. Protein quantification was performed using the BCA assay (Pierce).
Statistical analysis. Results were analysed by one-way ANOVA followed by Tukey’s multiple comparison 
test using GraphPad Prism 7.03 (GraphPad Software, San Diego, CA). Results are presented as the means ± SD or 
SEM. Means are considered significantly different from each other are indicated by P < 0.05, P < 0.01 or P < 0.001.
Results
S100P is expressed in human trophoblasts including anchoring columns in vivo. Different 
reports have aimed to establish the expression patterns of S100P in human tissues15,29; its highest expression is 
found in placenta, from which it was originally isolated and characterised13,14. Little, however, is known about the 
cell types that express S100P within the placenta as well as its overall levels during the different stages of gestation. 
Human embryonic placenta tissues obtained immediately after elective termination of pregnancy at different 
times of gestation were prepared and embedded in paraffin wax. The protein lysates from the different forma-
lin-fixed paraffin-embedded tissue sections were subsequently extracted, as previously described28, before protein 
levels were compared by SDS-PAGE and Western-blotting using antibodies to S100P and α-tubulin (Fig. 1A; full 
length blots are presented in Supplementary Fig. S2), and subsequent densitometric analysis performed (Fig. 1B) 
as well as following density analysis after immunohistochemistry of the different sections (Fig. 1C,D). The results 
show a reduction in levels of S100P as gestation progresses with levels reaching only 45% in the third trimester. 
(Fig. 1A,B,D). The decrease in S100P levels was seen to be significant throughout the gestational period between 
first trimester and second trimester (P = 0.0063 for Western blot analysis and P = 0.0287 for immunohistochem-
istry quantification) or third trimester (P = 0.095 for Western blot analysis and P = 0.0016 for immunohistochem-
istry quantification) but not between second and third trimester samples (P = 0.7568 for Western blot analysis 
and P = 0.3479 for immunohistochemistry quantification). This data suggests that S100P is predominantly highly 
expressed in the early stage of gestation, during the process of trophoblast implantation.
In order to determine the pattern of S100P expression in the different cell types of the placental tissues, 
paraffin-embedded sections from early gestational stages were stained for S100P, along with other different troph-
oblast markers, using immunohistochemistry techniques (Fig. 1C,E). We found that S100P was expressed in 
both human villous cytotrophoblasts and multinuclear syncytiotrophoblast structures of the placenta during the 
different stages of pregnancy (Fig. 1C). We also sought to investigate whether S100P expression was also present 
in the differentiating extravillous trophoblast populations in anchoring trophoblast columns (Fig. 1E). A strong 
S100P signal was observed within the extravillous trophoblast anchoring columns. Serial sections of placental 
villi stained for cytokeratin-7 and HLA-G confirmed the identity of the extravillous trophoblasts (Fig. 1E) and 
the presence of S100P expression at all proximal, middle and distal ends of the anchoring columns. Serially sec-
tioned samples were also tested for antibody specificity by staining with the respective secondary antibodies alone 
(Supplementary Fig. S1).
Taken together, these results show that the S100P protein is predominantly expressed in the trophoblasts cells, 
including the extravillous trophoblast subsets and their anchoring columns and that S100P levels appear to be 
highest at times when trophoblasts are the most invasive during the early stages of placental implantation.
S100P is expressed in human trophoblast Jeg-3 and Bewo cell lines but not in the cultured first 
trimester extravillous HTR8/SVneo cells. Having established that S100P is predominantly expressed 
in human trophoblastic cells in placental tissues, we sought to determine if its mRNA/protein expression could 
equally be observed in trophoblast cell lines in order to provide a tractable experimental system. HTR8/SVneo, 
DAB staining and intensity in 1st, 2nd and 3rd trimester serial sections. Data of an individual representative 
experiment is presented as the mean values ± SD of 3 independent samples (D). Statistical analysis (B,D) 
show ± SD compared to the first trimester samples of an individual representative experiment. *P < 0.05 
and **P < 0.01 (one way- ANOVA). Immunohistochemistry staining using a panel of trophoblast marker 
antibodies (cytokeratin 7 (CK7), HLA-G, integrin α6 (CD49F) and S100P antibody) and counterstaining on 
anchoring columns of serial human placental tissues was performed as described in Methods. Arrows indicate 
cytotrophoblast cells (CT), syncytium (ST). Stroma is also highlighted. Bar corresponds to 100 μm (E).
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BeWo and Jeg-3 cells have been shown to be invaluable lines to study trophoblastic functions in cultures22,30. 
Expression analysis for S100P in these lines, along with an S100P doxycycline-inducible HeLa A3 cell system 
(acting as both positive and negative controls23) was carried out by mRNA quantification (qPCR amplification, 
Fig. 2A) and by Western blotting for proteins (Fig. 2B; full length blots are presented in Supplementary Fig. S3). 
Whilst non-induced HeLa cells, acting as negative control, did not show any detectable levels of S100P by Western 
blotting (Fig. 2B) and only low background levels after qPCR, induced HeLa cells showed a 25–30 fold highly 
significant increase in the amount of S100P when quantifying either mRNA or protein. Interestingly, both Jeg-3 
and Bewo cells also presented significant levels of endogenously expressed S100P (P < 0.0001 compared to 
non-induced HeLa), corresponding to about half of those seen in the S100P-inducible system, as determined by 
either densitometric analysis or by calculating the 2∆CT (Fig. 2). When comparing the two different trophoblastic 
cell lines, it was found that significantly higher levels of 1.7 to 2 fold were seen in the Bewo line when compared to 
the Jeg-3 counterparts. Surprisingly, we were not able to detect any expression of S100P by either Western blotting 
or qPCR in the first trimester extravillous HTR8/SVneo trophoblast cell lines (Fig. 2A,B) with levels observed 
being even lower than in the HeLa non-induced cells.
In order to learn more about S100P cellular localisation in the different trophoblast cells, immunostaining 
was carried out together with staining for both actin and the nucleus (Fig. 2D). To first confirm the specificity 
of the staining, we sought to stain for the S100P protein in our inducible HeLa system. As expected, there were 
no detectable levels of fluorescence against S100P in the cells grown without doxycycline. Induction of S100P in 
the HeLa cells resulted in an increase in fluorescence with staining observed in both the nuclear and cytoplasmic 
regions of the cells, consistent with previous work related to S100P localisation in these cell lines23. The majority 
of S100P in Jeg-3 and Bewo cells was found in a nuclear and perinuclear location, as observed by its colocalisation 
with DAPI, but some was also seen in the cytoplasmic compartment (Fig. 2D white arrow). This result indicates 
that S100P may be localised both in the nucleus and cytoplasm of trophoblast cell lineages. Antibody specificity 
was determined by staining with the corresponding secondary FITC labelled anti-IgG antibody alone, resulting 
Figure 2. S100P is expressed in Jeg-3 and Bewo but not HTR8 EV trophoblast cell lines. HTR8, Bewo and Jeg-3 
cells, along with HeLa A3 induced for S100P expression (or their non-expressing counterparts), were grown for 
48 hours prior to collection for mRNA qPCR analysis (A) or 72 hours prior to collection for protein Western 
blotting (B). mRNAs were isolated using TRIS reagent followed by reverse transcription and quantitative 
PCR analysis using S100P and β-actin primers, as described in Methods. Data is presented as 2∆CT mean 
values ± SD of 3 independent samples of a representative experiment compared to the non-induced HeLaA3 
cells. **P < 0.0001 (one way- ANOVA). (A) For the protein levels, cells were collected and solubilised in 
Laemmeli buffer and equal loading were separated by SDS-PAGE electrophoresis. Western blotting was carried 
out and membranes probed for S100P or α-tubulin and cropped images are presented. (B) Expression levels of 
S100P were measured by densitometric analysis, normalised to α-tubulin and presented in comparison to the 
non-induced HeLa A3 cells as percentage mean values ± SD of 3 independent samples compared to the non-
induced HeLa A3 cells. **P < 0.0001 (one way- ANOVA). (C) For immunostaining, Bewo and Jeg-3 cells, along 
with HeLa A3 induced for S100P expression (or their non-expressing counterparts) were seeded on fibronectin-
coated coverslips and grown for 48 hours prior to fixation, permeabilisation and staining for S100P and actin. 
Cells were mounted and viewed using epifluorescence microscopy. (D) Images in the last row correspond to the 
focused regions of the highlighted cells. Bar corresponds to 25 μm.
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in very weak background levels (data not shown). This data demonstrates that detectable levels of endogenous 
S100P are expressed in some trophoblast cell lines and that both Jeg-3 and Bewo cells can be used as models to 
silence S100P expression, but that S100P levels need to be overexpressed in the HTR8/SVneo cells since none are 
detectable.
Knock down of S100P by siRNA in human trophoblasts Jeg-3 and Bewo cell lines. Having 
demonstrated the endogenous expression of S100P in Jeg-3 and Bewo trophoblast cell lines, we next wanted to 
determine if we could specifically down-regulate S100P levels by siRNA delivery in order to gain further under-
standing about its physiological roles. Two different siRNAs were tested to determine their efficacy in reducing 
S100P expression at both the mRNA level after 48 hours (Fig. 3A,D) and protein level 72 hours after treatment 
(Fig. 3B,C,E,F; full length blots are presented in Supplementary Fig. S4). Mock treatment did not result in any 
appreciable changes in the levels of S100P expression in either Jeg-3 or Bewo cells. However, the presence of 
S100P-targeted siRNA always resulted in a significant reduction of S100P levels, albeit with different effectiveness. 
In general S100P directed siRNA treatments were less effective in Bewo cells, leading to a maximum reduction of 
2.5 fold or 50–60% decrease in S100P expression compared to 9.7 fold or over 90% decrease in S100P expression 
in the Jeg-3 cells. Although a total silencing of S100P expression was not achieved, significant reductions in S100P 
levels were still observed, especially in the Jeg-3 lineage.
Figure 3. Specific knock-down of S100P in Jeg-3 and Bewo trophoblastic cell lines. Bewo and Jeg-3 cells were 
incubated in the presence of different S100P or control siRNAs for 48 hours prior to collection for mRNA qPCR 
analysis (A,D) or 72 hours prior to collection for protein Western blotting (B,C,E,F). mRNAs were isolated 
using TRIS reagent followed by reverse transcription and quantitative PCR analysis using primers for S100P 
and β-actin, as indicated in Methods. Data is presented as 2∆CT mean values ± SD of 3 independent samples 
of a representative experiment compared to non-treated control samples. ***P < 0.0001 (one way- ANOVA) 
(A,D). For protein levels, cells were collected and solubilised in Laemmeli buffer and equal loading were 
separated by SDS-PAGE electrophoresis. Western blotting was carried out and membranes probed for S100P or 
α-tubulin and cropped images are presented (B,E). Expression levels of S100P were measured by densitometric 
analysis, normalised to α-tubulin and presented as percentage mean values ± SD of 3 independent samples 
of a representative experiment compared to non-treated control samples. *P < 0.01 ***P < 0.0001 (one way- 
ANOVA) (C,F).
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Knock-down of S100P results in significant reductions in Jeg-3 and Bewo cell motility and 
migration. Since S100P can act as a regulator of cellular motility in multiple human cancer lines23,31–33, we 
sought to determine if S100P can similarly promote trophoblastic cell migration. Bewo and Jeg-3 cell migration 
(Fig. 4A,B) and chemotaxis (Fig. 5A,B) were monitored using Boyden and Dunn chamber assays, respectively, 
after S100P knock-down by siRNA delivery. Whilst mock treated samples demonstrated no significant changes in 
the number of cells able to migrate across the Boyden membranes (P = 0.068), Jeg-3 cells grown in the presence of 
siRNA4 or siRNA6 presented a significant reduction, by at least 50% (P < 0.0001), in the ability to do so (Fig. 4A). 
Treatment of Bewo cells with the same siRNAs resulted equally in significant reduction of motility (P < 0.0001; 
Fig. 4B). Thus, lowering the levels of S100P in trophoblast cells is responsible, at least in part, for a reduction in 
cell migration. Treatment of either Jeg-3 or Bewo cells with the other siRNAs also resulted in significant reduction 
in cell motility using this assay (Data not shown). By analogy with cancer cells23, these results suggest that S100P 
may affect cellular protrusions and/or cytoskeletal architecture. To decipher some of the underlying molecular 
mechanisms, we sought to stain components of focal adhesions and the actin cytoskeleton in control cells and in 
their S100P siRNA counterparts (Fig. 4C). Focal adhesion assembly and dynamics are key regulators of cellular 
motility, since the proteins complexed in these structures undergo profound remodelling over time34. One such 
protein, paxillin, has been shown to act as vital adapter that aggregates into the focal complex at early stages of 
their formation35. Punctate focal adhesion formation/maturation could be observed and characterised by their 
presence in small numbers and relatively punctate in size in the control cell lines. Upon incubation with siRNA4 
and siRNA6, and a consequent reduction in S100P levels, clear increases in both the number and sizes of focal 
adhesions were observed (Table 1 and Fig. 4C). Quantitative analysis demonstrated a significant increase in num-
bers of focal adhesions by over 65% and 80% in Bewo and Jeg-3 cells respectively (Table 1) when cells were treated 
Figure 4. Specific reduction of S100P by siRNA technology leads to significant impairment in cellular motility 
of Jeg-3 and Bewo trophoblast cells. Bewo and Jeg-3 cells were treated with different S100P siRNAs (siRNA4 
and siRNA6) or mock-control for 48 hours prior to starvation with low serum-containing medium. 24 hours 
later, cells were seeded into Boyden chambers for 16 hours prior to fixation and staining using the Diffquik 
histochemical kit for labelling of both nuclei and cytoplasm. (A,B) 5 random fields were quantified for each 
chamber. Data is presented as means ± SEM of 4 independent experiments relative to controls (percentage) 
from 4 replicate wells for each set of conditions. ***P < 0.0001 compared to control and mock treated (one 
way-ANOVA). After siRNA delivery, and a further 48 hours incubation, cells were seeded on fibronectin-
coated coverslips and grown for a further 48 hours prior to fixation, permeabilisation and staining for the 
focal adhesion marker paxillin and the cytoskeletal marker actin. Cells were mounted and viewed using 
epifluorescence microscopy. (C) Images on the last row correspond to the focused regions of the highlighted 
cells. Bar corresponds to 50 μm. Images of representative fields of motility/invasion assays were taken with the 
EVOS XL Cell Imaging System at x20 magnification.
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with either S100P siRNA4 or siRNA6 in comparison to control/mock-treated cells. Changes in actin cytoskeletal 
organisation were also seen when both cell lines were incubated with siRNA4 and siRNA6 (Fig. 4C). Untreated 
and mock control (data not shown) trophoblast cells demonstrated large arrangements of lamellipodia at the 
leading edges. Only small arrays of fibrillar actin could be observed and these rarely formed focal adhesions. 
Figure 5. Specific reduction of S100P by siRNA leads to a reduction in distance of migration of Jeg-3 
trophoblast cells. Jeg-3 cells treated with different S100P siRNAs (siRNA4 and siRNA6) or control mock for 
48 hours were used either for quantitative chemotaxis-directed motility (A,B) or directional migration after 
wounding. (C) For chemotaxis, cells were first starved with low serum-containing medium for 24 hours prior 
to seeding on fibronectin coated coverslips in a Dunn chamber (A,B) against high serum containing medium. 
Digitised images were obtained using the Cell IQ automated image capture system, (Chip-Man Technologies) 
in which pre-selected fields were imaged using phase contrast microscopy on a continuous loop. Data collected 
was analysed using ImageJ and chemotaxis and migration software in order to analyse chemotaxis and 
distance of migration. Data is presented as mean values ± SD of 3 independent samples of a representative 
experiment compared to non-treated control samples. ***P < 0.0001 (one way-ANOVA). (B) For the wound 
healing experiment, cells were seeded on fibronectin-coated coverslips for 48 hours prior to attaining 100% 
confluency, scratched and grown for a further 16 hours prior to fixation, permeabilisation and staining for 
the focal adhesion marker paxillin and the cytoskeletal marker actin. Cells were mounted and viewed using 
epifluorescence microscopy. (C) Images in the last column correspond to the focused regions of the highlighted 
cells. Bar corresponds to 50 μm.
Cell lines
Percentage focal adhesions 
per cell ± SEM (n = 50) P-valuea P-valueb
Jeg3 control 100 ± 2.22
Jeg3 treated with S100P siRNA4 177.08 ± 4.54 P < 0.0001
Jeg3 treated with S100P siRNA6 190.38 ± 3.67 P < 0.0001 0.4916
Bewo control 100 ± 1.85
Bewo treated with S100P siRNA4 166.16 ± 3.04 P < 0.0001
Bewo treated with S100P siRNA6 171.57 ± 3.99 P < 0.0001 0.9033
Table 1. Reduction of S100P in trophoblast cells leads to increases in the number of focal adhesions per cell. 
Jeg-3 and Bewo control cells, as well as cells treated with different S100P targeted siRNA for 72 hours were fixed 
and stained for paxillin and actin after seeding on fibronectin-coated coverslips. Data shown are means ± SEM 
corresponding to the average number of focal adhesion-containing paxillin observed per cell, presented as 
percentage of control. Untreated and mock treated controls (data not shown) were found to be not statistically 
significant (P > 0.05). aP-value obtained from one-way ANOVA where total number of focal adhesions present 
in Jeg-3 or Bewo control cells were compared to previously S100P siRNA-treated counterparts. bP-value 
obtained from one-way ANOVA where total number of focal adhesions present in Jeg-3 or Bewo cells treated 
with siRNA4 were compared to siRNA6-treated counterparts.
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Upon treatment with S100P siRNAs, large bundles of actin filaments could be seen at the cell periphery, resulting 
in reciprocal numbers of focal adhesion formations (Fig. 4C).
Because migration rates in Boyden chambers can be influenced by serum chemotaxis, we sought to deter-
mine whether the S100P-dependent changes in motility reported thus far were the result of increased motility or 
linked to the directional responsiveness of trophoblastic cells. To further this aim, directional cellular migration 
was observed in Jeg-3 cells by staining cells at the edge of a wound-healing scratch (Fig. 5C), or through their 
migration in Dunn chambers (Fig. 5A,B). When S100P expression in Jeg-3 cells was reduced, there was no signif-
icant effect on overall chemotaxis abilities, since all cells used, whether siRNA-treated or non-treated controls, all 
demonstrated efficient directional motility towards cues by moving in the same direction (Fig. 5A). By contrast, 
the presence of S100P was seen to have significant effects on the overall distances of cell migration (P < 0.0001; 
Fig. 5B). Thus whilst untreated or mock-treated samples were shown to have similar properties of migration rates, 
siRNA4 or siRNA6 delivery significantly reduced by 40%, the overall distance of migration of the Jeg-3 cells. 
These results are in line with the 50% decreases that had been observed when performing Boyden chamber assays.
To provide further information about the cellular changes taking place, we analysed components of focal 
adhesions in control cells and S100P siRNA-treated counterparts, in directionally migrating cells after scratch 
wounding (Fig. 5C). Once scratched, cells at the edge of the wound move in the newly created space, demonstrat-
ing a specific directional migration in the process36–38. After scratching, control and mock-treated trophoblasts 
established a small number of focal adhesion clusters, as determined by the formation of paxillin foci, at the cellu-
lar periphery (Fig. 5C and Table 2). However, when treated with either siRNA4 or siRNA6, a clear and significant 
increase of around 60% in the number of foci was seen per cell, suggesting that S100P downregulates the number 
and possibly maturation of focal adhesions at the leading edge of migrating cells.
High levels of S100P in trophoblasts have been linked to increased cell viability and cellular proliferation in 
the choriocarcinoma JAR cell line19. To verify whether the effects on cellular motility in the Jeg-3 and Bewo cells 
were related to reduced cell viability, we measured cell growth over 48 hours after S100P levels had been knocked 
down and therefore well within the time frame used to measure migration (Fig. 8A for Jeg-3 and data not shown 
for Bewo). None of the siRNA treatments resulted in a significant reduction of the cell numbers (P > 0.96 for 
all conditions tested) and hence cell viability was probably not compromised in our experiments as cells were 
proliferating normally over the course of the experiment, with a doubling of the population in about 24 hours 
indicating that the defects seen in motility are not due to reduction in cell numbers.
Taken together, this data demonstrates that the S100P protein can play an important role in the migratory 
rates of trophoblast cells and that reducing its expression levels results in a significant impairment in motility as 
well as affecting the overall actin cytoskeleton and the number of focal adhesions.
Knock-down of S100P results in significant changes in Jeg-3 and Bewo cell invasion. Given 
the well-established role for S100P in promoting cancer cell invasion, we assessed whether S100P could regulate 
the invasiveness of Jeg-3 and Bewo cells. Jeg-3 cells which had been previously treated for 48 hours with siRNA4 
and siRNA6 targeted towards S100P, or the corresponding controls, were starved for serum for 24 hours prior to 
seeding on congealed matrigel in Boyden chambers and allowed to invade the gel in the membrane. The untrans-
fected Jeg-3 cell controls as well as the mock-treated counterparts demonstrated good abilities to invade through 
Matrigel with no significant changes between them (Fig. 6). S100P siRNA treated Jeg-3 cells, however, showed a 
significant reduction in their ability to invade into the matrigel (P < 0.0001 compared to control or mock treated), 
lowering the number of cells capable of reaching the outer side of the membrane by more than 70% (Fig. 6A). 
Inhibition of invasion of Bewo cells using the same strategy was equally significant, causing a reduction of over 
50–60% when treated with S100P directed siRNA compared to control counterparts (P < 0.0001; Fig. 6B).
All together the data demonstrates that reducing the expression of endogenous S100P in cultured Jeg-3 and 
Bewo trophoblastic cells causes them to decrease their ability to migrate, and more significantly, to invade.
Overexpression of S100P in the first trimester extravillous HTR8/SVneo cell line leads to increased 
cellular motility and invasion. To determine whether the S100P effects reported so far on cell 
Cell lines
Number of focal adhesions 
per cell ± SEM (n = 15) P-valuea P-valueb
Jeg-3 control 100 ± 1.98
Jeg-3 mock control 106.13 ± 2.22 0.2858
Jeg-3 treated with S100P siRNA4 160.65 ± 3.55 P < 0.0001
Jeg-3 treated with S100P siRNA6 166.87 ± 3.06 P < 0.0001 0.9201
Table 2. Reduction of S100P in trophoblast cells leads to increases in the number of focal adhesions per 
migrating cell. Jeg-3 control cells, as well as mock treated cells and cells incubated with different S100P targeted 
siRNA for 72 hours were grown until fully confluent prior to wound healing and grown for a further 16 hours 
before being fixed and stained for paxillin and actin. Data shown are means ± SEM corresponding to the 
average number of focal adhesions containing paxillin observed per cell at the leading front, presented as 
percentage of control. Untreated and mock treated controls (data not shown) were found to be not statistically 
significant (P > 0.05). aP-value obtained from one-way ANOVA where total number of focal adhesions presents 
in Jeg-3 or Bewo control cells were compared to previously S100P siRNA-treated counterparts. bP-value 
obtained from one-way ANOVA where total number of focal adhesions present in Jeg-3 or Bewo cells treated 
with siRNA4 were compared to siRNA6-treated counterparts.
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Figure 6. Specific reduction of S100P by siRNA leads to significant impairment in invasive abilities of Jeg-3 
and Bewo trophoblast cells. Jeg-3 (A) and Bewo (B) cells were treated with different S100P siRNAs (siRNA4 
and siRNA6) or control siRNAs for 48 hours prior to starvation with low serum containing medium. 24 hours 
later, cells were seeded in Boyden chambers previously coated with matrigel and incubated for 16 hours 
prior to fixation and staining using the Diffquik histochemical kit for labelling of both nuclei and cytoplasm. 
(A,B) 5 random fields were quantified for each chamber. Data is presented as means ± SEM of 4 independent 
experiments relative to controls (percentage) from 4 replicate wells for each set of conditions. ***P < 0.0001 
compared to control and mock treated (one way- ANOVA). Images of representative fields of motility/invasion 
assays were taken with the EVOS XL Cell Imaging System at x20 magnification.
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migration and invasion can be reciprocated in a first trimester cell line, similar work was carried out using the 
well-established and characterised HTR8/SVneo cell line. Since S100P levels could not be detected in this line 
either by Western blotting or qPCR analysis (Fig. 2A; full length blots are presented in Supplementary Fig. S5; 
and 2B), stable transfected clones were engineered to overexpress S100P (Fig. 7A). The control clone 3 transfected 
with the empty backbone pcDNA3.1 hygromycin-B plasmid produced no detectable levels of S100P in contrast 
to both clones 5 and 7 transfected with the S100P containing plasmid SGB217 which demonstrated significant 
expression of the S100P protein, corresponding to a 20–40% increase over that of the Jeg-3 cells (Fig. 7A,B).
These high expressing clones were then used to determine the cells’ ability to migrate and invade using differ-
ential Boyden chamber assays. High levels of S100P expression in clones 5 and 7 resulted in significant increases 
in cellular motility and invasive traits (P < 0.0001). Whilst migration was significantly increased by about 100 and 
250% for clone 7 and 5 respectively, compared to control clone 3, invasion was seen to be even more dramatically 
increased, with numbers reaching up to 5 fold for clone 7 and 8 fold for clone 5 respectively.
Because regulating levels of S100P has been shown to affect viability and growth of the HTR8/SVneo cells18, 
we sought to determine whether high expression of S100P in these cells would affect cell numbers and therefore 
be responsible, at least in part, for the large effects reported here on cell motility and invasion. Despite the large 
excess in S100P expression seen in HTR8/SVneo expressing clones 5 and 7 compared to the control cells, we were 
not able to find any significant changes in cell proliferation and growth (P > 0.96 for all conditions tested) when 
assessing cell numbers over a 48-hour time, as cells were all seen to be growing normally with a doubling of the 
cell population about every 24 hours (Fig. 8B). These results demonstrate that overexpression of S100P signifi-
cantly increases both motility and invasion in the first trimester extravillous HTR8/SVneo cell line.
Discussion
S100P expression has been linked to progression of malignancy of cells originating from numerous tissue sources, 
such as breast, pancreas and lung39–44 with supporting evidence showing that S100P acts a regulator of cellular 
invasiveness and motility in multiple human carcinoma cell lines23,31–33. In this report, we offer the first evidence 
that expression of S100P can stimulate trophoblast cell motility and invasive properties, therefore supporting a 
new potential physiological role for S100P in the process of trophoblast implantation.
Figure 7. Overexpression of S100P in HTR8/SVneo trophoblast cells leads to significant increases in motility and 
invasive abilities. Stable transfection of HTR8/SVneo cells with S100P cDNA in pcDNA3.1 hygromycin plasmid 
was established to isolate clones expressing different levels of S100P, or their counterpart control, and protein levels 
assessed by Western blotting (A). Cells were collected and solubilised in Laemmeli buffer at equal loading and 
were separated by SDS-PAGE electrophoresis. Western blotting was carried out and membranes probed for S100P 
or α-tubulin and cropped images are presented (A). Expression levels of S100P were measured by densitometric 
analysis, normalised to α-tubulin and presented in comparison to the control untreated equivalent cells (B). Error 
bars in (B) show ± standard deviation compared to untreated control samples from a representative experiment. 
***P < 0.001 compared to control (one way- ANOVA). The same clones expressing different levels of S100P 
were seeded in either Boyden chambers alone or chambers previously coated with matrigel. Cells were incubated 
for 16 hours prior to fixation and staining using the Diffquik histochemical kit for labelling of both nuclei and 
cytoplasm. 5 random fields were quantified for each chamber. Data is presented as a percentage compared to the 
control untreated cells for cell motility (C) or invasion (D). Error bars in (C,D) show means ± SD of 3 independent 
experiments relative to controls (percentage) from 4 replicate wells for each set of conditions. **P < 0.005 and 
***P < 0.0001 compared to control cells (one way- ANOVA). Images of representative fields of motility/invasion 
assays were taken with the EVOS XL Cell Imaging System at x20 magnification.
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Recent reports suggest that S100P is expressed at high concentrations in trophoblast cells in vitro and in 
vivo15,18,19,45 with most results obtained in tissue culture as a result of global proteomic analysis45. Our work fur-
ther supports the observation that S100P is actively expressed in trophoblast cells both in culture and in vivo 
(Figs 1 and 2). Furthermore, our analysis of S100P expression over the full gestation period demonstrates that 
its protein levels are highest during the early stage of implantation (first trimester), significantly reducing by 
50% during the second and third trimester of gestation (Fig. 1). Such results corroborate, at least in part, those 
reported recently by Zhu et al.19 which also shows higher concentration of the protein in the early stages of 
placentation (first trimester) compared to the gestational second trimester period. However, whilst expression 
remained significantly lower during the final trimester of gestation in our work (Fig. 1), S100P expression in term 
placental tissues was seen to increase again in Zhu et al.19, suggesting potential functions of this protein during 
delivery. This observation shows that, during gestation, S100P levels peak in trophoblast cells when they are 
the most invasive46 and suggests that S100P could potentially be a regulator of this cellular process. In line with 
this reasoning, other proteins whose functions are essential during trophoblast invasion in implantation such as 
laminin α4 (LAMA4)47, placental protein 1 (PLAC1)48 and CUL149 to cite just a few, have also been shown to be 
specifically highly expressed in the early stages of placentation. Similarly, other proteins of the S100 family such 
as S100A8 (MRP8) have also been found to be expressed in trophoblasts12,50 and its expression levels mirrored 
that of our work; that is, high levels found in the early stages of gestation with reducing levels as the pregnancy 
approached full term. The full implications of the expression of specific S100 proteins in early stages of tropho-
blast implantation needs to be explored further.
Immunohistochemistry analysis of the same tissues confirmed the reduction of S100P expression over time, 
whilst also clearly demonstrating the specific labelling of all trophoblasts (Fig. 1). In the first trimester, clear 
staining for S100P protein could be seen specifically in syncytiotrophoblasts as well as in cytotrophoblasts and 
extravillous trophoblasts in anchoring columns (Fig. 1E). In the latter, S100P expression colocalised with staining 
for HLA-G in the middle and distal extravillous populations in vivo. Whilst we have studied S100P as a stimulator 
of cellular motility and invasion in trophoblasts because of its presence in anchoring columns, it is clear that its 
expression in large amounts in the syncytiotrophoblasts suggests that it may confer other properties to placental 
Figure 8. Modulation of S100P protein levels does not affect Jeg-3 and HTR8 trophoblast cell proliferation. 
Jeg-3 cells were treated with different S100P siRNAs (siRNA4 and siRNA6) or mock-control for 48 hours prior 
to seeding (A). Stably transfected HTR8/SVneo cells expressing S100P or the control counterpart were grown 
as described in methods (B). Cell lines were seeded into 24 well plates and left to grow for a further 24–48 hours 
before trypsinisation and removal from the wells and counting using trypan blue exclusion. Data is presented as 
percentage means ± SD of 3 independent experiments relative to controls from 3 replicate wells for each set of 
conditions. ***P < 0.0001 (one way-ANOVA).
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development and may therefore be involved in events regulating the maternal-foetal interface. Further work is 
needed to explain other physiological functions of this protein during placentation.
Whilst all types of trophoblasts in tissues (Fig. 1.) as well as primary extravillous trophoblast cells isolated 
from first trimester placental tissues express high levels of S100P (Data not shown), no S100P was detected in 
the first trimester extravillous HTR8/SVneo cell line. Absence of S100P expression in this HTR background has 
recently been documented following global proteomic analysis51 whilst another group were able to detect its 
expression18. This discrepancy is difficult to explain, since we have been unable to get any positivity by either PCR 
or Western blotting, with quantitative analysis from both experiments demonstrating levels well below that of 
our negative control lines (Fig. 2). This could possibly be due to the fact that these cells have been obtained from 
two different sources, since S100P non-expressing HTR8/SVneo have been obtained directly from their creator 
(Graham Charles (Queen’s University, Kingston, Ontario (Canada)), whilst the others have been purchased from 
a cellbank. Whilst it is surprising that S100P was not found to be expressed in our HTR8 cell background, there is 
evidence of certain markers known to be present in extravillous trophoblast primary cultures and tissues which 
are not seen in this cell line. For example, expression of cytokeratin 7, HLA-G and E-cadherin have been reported 
as being absent in the HTR8/SVneo background, when in contrast, they are highly expressed in different tropho-
blast subtypes52–56. Similarly it is not uncommon for SVneo transformed cell lines to lose their abilities to express 
markers characteristic of their parental differentiated state when grown in tissue culture57. Furthermore, it has 
been shown that the use of matrigel is required to drive HTR8/SV neo cells into an EVT like cell phenotype58,59, 
regulating the expression of matrix metalloproteinases and integrin α1 for example. All experiments using the 
HTR8/SVneo cells performed in our work did not use matrigel, at least during studies related to their expression. 
Further work will be required to demonstrate if S100P can indeed be regulated as other genes considered to be 
markers of invasive EVT, when grown on matrigel.
Staining to establish the cellular localisation of endogenously expressed S100P demonstrated its presence in 
both the cytoplasm and nuclear domains of trophoblasts in vivo and in culture using the Jeg-3 and Bewo cell lines 
(Figs 1 and 2). Such observations have also been reported in other cells, both in tissues or lines, mainly in cancer 
states23,41,60,61 and demonstrated again with our HeLa cells (Fig. 2), suggesting that different pools of S100P may 
have differential functions, all which remain to be clearly identified and established both in cancer cells and in 
trophoblasts.
One such S100P dependent function that is widely accepted is its ability to promote cell migration and inva-
sion62. In order to assess whether such properties could be affected in trophoblasts, the Jeg-3, Bewo and HTR8/
SVneo cell lines were used as they provide a tractable experimental system recognised as an appropriate model for 
motile and invasive trophoblast behaviour22,63,64. We have now demonstrated here that S100P can play a pivotal 
role in regulating trophoblastic motility and invasion in cultured cells. Reducing S100P expression, especially in 
Jeg-3 cells, led to significant changes in migration distances (Fig. 5) and overall motility (Fig. 4), as well as a dra-
matic reduction in invasion (Fig. 6). Results obtained using Bewo cells also demonstrated clear defects in motility 
and invasion (Figs 4–6) but were somewhat reduced due to a less effective ability of delivered siRNAs to lower 
S100P expression (Fig. 3). This is in line with other work which has shown that siRNA treatment is less effective in 
Bewo cells compared to other trophoblast cell lines for targets such as tissue factor pathway inhibitor-2 (TFPI-2) 
or lasp-165,66. In the reciprocal experiment using HTR8/SVneo cells, where no detectable amount of S100P could 
be seen, upregulating levels of S100P resulted in a dramatic improvement in both cell motility and invasion, 
with the latter being increased 10-fold in our higher expression clone. Modulation of gene expression improving 
both motility and invasion of the HTR8/SVneo cells has been reported, where for instance, expression of MSH 
homeobox 267, CDX268 and smurf269 or the presence of Sphingosine-1-phosphate70 have been shown to increase 
invasion, albeit not to the levels that were seen in our experiments. This further demonstrates that despite the fact 
that S100P is not expressed in the HTR8/SVneo line, the molecular circuitry required for the S100P dependent 
pathway regulating both motility and invasion are present and further offer an invaluable model to further study 
the molecular mechanisms of such process.
This observation that S100P stimulates motility and invasion in trophoblast cells is consistent with some of 
the postulated roles for S100P in carcinoma cell lines23,42,71–73 as well as the process of metastasis in animals72,73, 
but as yet, has never been identified with a physiological process. In the context of this work, it highlights for the 
first time that S100P promotes migratory and invasive properties in human trophoblast cell lines and that, in line 
with its high expression during the first trimester in anchoring columns, further suggests a potential role for this 
protein in the process of implantation.
The clear mechanisms regulated by S100P to promote such changes in cellular motility and invasiveness are yet 
to be explained. Over the years, different target proteins such as ezrin61, IQGAP174, non-muscle myosin IIA23 or 
proteins related to the tissue plasminogen activator pathway75 have been shown to act as S100P binding partners 
in normal and cancer cells where they are believed to regulate motility and invasion. Interestingly, ezrin knock-
down has been shown to play key roles during gestation leading to foetal growth retardation76, whilst non-muscle 
myosin IIA is essential during embryogenesis and placentation77 and may regulate cellular motility of tropho-
blasts in culture78. However, a role for IQGAP1 and tissue plasminogen activator in trophoblast motility/invasion 
are yet to be characterised, but both have been shown to be key regulators of cancer motility/invasion79–81.
Our work here demonstrates that significant changes in the overall actin architecture takes place in tropho-
blasts when S100P levels are reduced. Less prominent motile features such as the formation of the leading edge 
can be observed (Figs 4 and 5). The actin cytoskeleton is a key regulator of cell migration and invasion, where 
the rearrangement of specific cellular structures known as lamellipodia and filopodia play an essential role82. 
Remodelling of the actin cytoskeleton has been closely linked to changes in cell motility in different cell lines as 
well as trophoblasts83–85. In this work, we show that reducing S100P levels via siRNA delivery leads to significant 
changes in the overall shape of the actin cytoskeleton, including the formation of large arrays of actin fibres at 
the cell periphery (Fig. 4) and the disappearance of lamellipodia spatial organisation. This concept is in line with 
www.nature.com/scientificreports/
1 5ScIentIfIc RepoRts |  (2018) 8:11488  | DOI:10.1038/s41598-018-29852-2
previous observations that show that actin cytoskeletal integrity is critical for trophoblast differentiation and 
motility/invasion since highly motile undifferentiated trophoblast cells demonstrate prominent protrusions and 
less stress fibers/actin filament formation than their more differentiated counterparts in rat cells86. Equally, actin 
protrusion can be seen as a marker of cellular motility/invasion since treatment inhibiting LIMK was seen to both 
reduce overall actin remodelling at the leading edge and the general invasiveness of primary human cytotroph-
oblasts87. Whilst focal adhesion maturation and dynamics are key components of general cell motility, little is 
known about this process in trophoblasts. Motility of trophoblasts related to focal adhesion maturation is not well 
described, but reports have highlighted the importance of focal adhesion formation in trophoblasts85,88–90. We 
show here that reducing the levels of S100P by siRNA targeting in trophoblast cells results in a significant increase 
in the number and potential maturation of focal adhesions, given the clear changes in their number and size 
(Figs 4 and 5). Such observations are consistent with changes in cell motility, as more dynamics and less estab-
lished focal adhesions have been demonstrated to be essential for migration, at least in carcinoma cell lines25,91,92 
and also trophoblasts86. Similarly, changes in paxillin recruitment and focal adhesion kinase phosphorylation, 
both markers of focal adhesion maturation, have also been reported in trophoblasts85,93,94. The clear mechanisms 
by which S100P could remodel the actin architectures and focal adhesion assembly, as well as stimulate both cel-
lular motility and invasion of trophoblasts, remain to be characterised.
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